trap

nociceptin/orphanin FQ (NOP) receptor antagonist

Scrambled TRAP Fragment is a variant of the TRAP Fragment compound, characterized by its random amino acid sequence. It is typically employed as a negative control due to its similarity in composition to the active fragment.

TRAP-6 amide, a PAR-1 thrombin receptor agonist peptide, [Cyclo(Pro-Arg-Gly)-Arg-Ser-Gly], is derived from the primary sequence of [TRAP-2].

TRAP-6 amide acetate is a PAR-1 thrombin receptor agonist peptide[1].

TRAP-6 amide TFA is a thrombin receptor agonist peptide targeting PAR-1.

TRAP-6 (Thrombin Receptor Activator Peptide 6)(2TFA) is an agonist of protease-activated receptor 1 (PAR1).

iso-TRAP-6 (iso-SFLLRN), a hexapeptide derived from the substitution of isoserine for serine, is a protease-activated receptor 1 (PAR1) agonist that activates platelets via PAR-1. iso-TRAP-6 is more resistant to degradation by plasma aminopeptidases than iso-TRAP-6.

Hamamelitannin has cytotoxic, and antibiofilm activities. It increases the susceptibility of S. aureus to antibiotic treatment in in vivo Caenorhabditis elegans and mouse mammary gland infection models. It also has a high protective activity on cell damag

NFAT Inhibitor (VIVIT peptide) is a cell-permeable compound that selectively inhibits the calcineurin-mediated dephosphorylation of NFAT.

Aflibercept is a recombinant fusion protein antibody composed of the Ig domains of VEGFR1 and VEGFR2 and the Fc domain of human IgG1. Aflibercept inhibits VEGF signaling and is a commonly used tool in biological research for suppressing pathological angiogenesis.

H-Ser-Phe-Leu-Leu-Arg-OH, also known as Coagulation Factor II Receptor (1-5) or Proteinase Activated Receptor 1 (1-5), is utilized in coronary heart disease (CHD) research.

FLLRN is a biologically active peptide serving as a PAR1-specific antagonist.

PU-H54 is a purine-based inhibitor of Grp94. It is a Grp94-selective resorcinol-based inhibitor isolated through probing of the exclusive binding region of S2 subpocket in Grp94.

TRAP-6-IN-1 (Compound 8) is a dual inhibitor of collagen and TRAP-6 with IC50 values of 17.12 μM and 11.88 μM, respectively. It non-competitively inhibits agonist-induced platelet aggregation[1].

TRAP-5 amide is a peptide agonist for protease-activated receptor 1 (PAR 1) [1].

TRAP-14 amide is a protease-activated receptor (PAR) activating peptide and acts as a PAR agonist, with an EC50 of 24 μM. It induces significant platelet aggregation via ADP and MMP-2 dependent pathways and is insensitive to Aspirin. Additionally, TRAP-14 amide effectively increases the surface expression of glycoprotein (GP) Ib and GPIIb/IIIa, as well as the release of ADP.

TRAP-1 (XJZ-06-462) is a p53 transcription activator that effectively activates mutant p53 and triggers the transcription of p53 target genes. In the p53Y220C pancreatic cell line, TRAP-1 rapidly upregulates p21 and other p53 target genes. TRAP-1 also inhibits cell proliferation, exhibiting IC50 values of 3.94 μM and 0.531 μM in BxPC-3 and A549 cell lines, respectively. Additionally, TRAP-1 modulates autophagy in lung cancer cells and provides protection against oxidative stress and apoptosis.

TRAP-6 peptide is a hexapeptide corresponding to residues 42-47 of protease-activated receptor 1 (PAR1). It acts as an agonist of PAR1, inducing platelet aggregation in human platelet-rich plasma ex vivo (EC50 = 0.8 μM). TRAP-6 (0.3 and 0.6 mg/kg) has a triphasic effect on mean arterial blood pressure (MAP) in anesthetized rats with a short decrease, an increase, and then a longer decrease in MAP following intravenous administration.

TRAP-7, a thrombin receptor (PAR) activating peptide, stimulates total inositol phosphate (IP) accumulation and phosphorylation of a specific endogenous substrate for activated PKC. TRAP-7 can be utilized in cardiovascular disease research [1].

TRAP1-IN-1 (compound 35) is a selective TRAP1 inhibitor that disrupts TRAP1 tetramer stability, induces degradation of TRAP1 downstream proteins, inhibits OXPHOS, and disrupts mitochondrial membrane potential.

TRAP1-IN-2, also known as compound 36, is a selective degrader of the TRAP1 client protein that does not affect Hsp90-cytosolic clients. It inhibits oxidative phosphorylation (OXPHOS) and shifts cellular metabolism toward glycolysis. Additionally, TRAP1-IN-2 compromises the stability of the TRAP1 tetramer and disrupts the mitochondrial membrane potential [1].

Obicetrapib (AMG-899) is an inhibitor of cholesteryl ester transfer protein.

Trapencaine is a newly synthesized carbamate type local anesthetic that induces conformational changes in sodium channels on hypertrophic cell membranes.

Tetrapeptide-30 Acetate (Tetrapeptide-30 Acetate) is a synthetic peptide containing the amino acids proline, glutamic acid, and lysine. It acts on and within specific targets of skin to reduce factors and interrupt the pathways that lead to the appearance of discolorations and uneven skin tone.